Narrow Results Clear All
Search results for "Opiates/Narcotics"
- Medical Oncology
Journal Article > Commentary
Clinicians' perceptions of medication errors with opioids in cancer and palliative care services: a priority setting report.
Heneka N, Shaw T, Azzi C, Phillips JL. Support Care Cancer. 2018;26:3315-3318.
This commentary explored organizational opioid incident review experiences from six hospitals in Australia to set priorities for improvement. The authors determined where process errors occurred, reviewed what factors were involved, and discussed error reduction strategies. They suggest their findings can inform future opioid safety efforts for oncology and palliative care patients.
Journal Article > Review
Quantifying the burden of opioid medication errors in adult oncology and palliative care settings: a systematic review.
Heneka N, Shaw T, Rowett D, Phillips JL. Palliat Med. 2016;30:520-532.
Opioids are commonly used to manage pain in patients with cancer and those near the end of life. Although opioids offer many therapeutic benefits, they are also a known high-risk medication. Deaths due to inadvertent opioid overdose are a major patient safety issue in ambulatory care, and this review sought to quantify how often opioids were implicated in adverse drug events in oncology and palliative care patients. Despite a broad literature search, the authors identified only a few relevant studies, most of which examined errors associated with opioid prescribing in hospitalized patients. As a result, it was not possible to estimate the incidence of opioid-related medication errors in this population. This lack of data hinders better understanding of the balance between risks and benefits of opioids in ambulatory care patients, which is very important given how frequently opioids are used for cancer pain. The AHRQ Health Care Innovations Exchange offers tools for organizations seeking to optimize opioid prescribing. A WebM&M commentary discussed a case of a death due to an unintentional opioid overdose.
MedWatch Safety Alert. Silver Spring, MD: US Food and Drug Administration; September 13, 2007.
This announcement provides specific instructions on safe prescribing of a cancer pain medication in response to several patient deaths associated with off-label use.